The recent $465 million settlement between Mylan and the U.S. Justice Department over the EpiPen apparently will do nothing to harm the multi-million-dollar pay packages enjoyed by Mylan CEO Heather Bresch and other top executives.

A review of the drug company’s 2015 proxy filing with data going back eight years shows that, like a number of other big companies, Mylan excludes such litigation costs when calculating incentive pay for its top executives.

The proposed settlement with the Justice Department announced early this month — which resolves allegations that Mylan overcharged Medicaid for the potentially life-saving allergy treatment — amounts to nearly half of EpiPen’s annual sales.

The deal, which will be scrutinized during a Senate Judiciary Committee hearing next month, came amid weeks of outrage over the soaring price of the auto-injector, which has risen some 500 percent in recent years.

Advertise with us

One large Mylan shareholder believes executives should feel the sting over the Medicaid issue.

“It would be grossly inappropriate for Mylan to exclude the cost of this penalty when determining incentive pay for top executives,” New York City comptroller Scott M. Stringer said in an email.

“The executives enjoyed lucrative payouts in the past for performance that turns out to have been based on improper conduct,” said Mr. Stringer, who oversees pension funds holding about 1 million Mylan shares.

The pension funds have been critical in the past of Mylan’s pay practices, and in September called for an overhaul of Mylan’s board citing missteps regarding the EpiPen.

Mylan did not return emails Friday seeking comment. In the past, the company has noted that the Justice Department settlement did not include an admission of wrongdoing.

Advertise with us

Ms. Bresch was paid $18.9 million last year, which included a $1.3 million salary, plus stock awards, incentives and other compensation.

In a separate matter, Mylan has disclosed that it will shutter the Somerset, N.J.-based U.S. headquarters of its newly-acquired Swedish specialty drug maker Meda at year end.

The move, contained in a filing with the state of New Jersey, will eliminate 94 jobs.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.